Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Laurence Lodé,Audrey Ménard,Laurent Flet,Steven Richebourg,Marion Loirat,Marion Eveillard,Yannick Le Bris,Catherine Godon,Olivier Theisen,Anne-Laure Gagez,Guillaume Cartron, Thérèse Commes-Maerten,Bruno Villemagne,Odile Luycx,Pascal Godmer,Catherine Pellat-Deceunynck,Thierry Soussi,Marie C Béné,Jacques Delaunay,Pierre Peterlin

Haematologica（2017）

引用 36|浏览44

暂无评分

摘要

The cytogenetic anomaly of isolated del(5q) characterizes a subgroup of patients with lower-risk myelodysplastic syndrome (MDS). In the 2016 World Health Organization classification, one additional karyotypic abnormality (except −7 or del7q) can be present in such patients.[1][1] Median survival

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要